Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early Discharge from the Emergency Department Based on Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels: A TRIAGE III Substudy.
Schultz M, Rasmussen LJH, Høi-Hansen T, Kjøller E, Jensen BN, Lind MN, Ravn L, Kallemose T, Lange T, Køber L, Rasmussen LS, Eugen-Olsen J, Iversen KK. Schultz M, et al. Among authors: kallemose t. Dis Markers. 2019 May 19;2019:3403549. doi: 10.1155/2019/3403549. eCollection 2019. Dis Markers. 2019. PMID: 31236143 Free PMC article. Clinical Trial.
Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department.
Stauning MA, Altintas I, Kallemose T, Eugen-Olsen J, Lindstrøm MB, Rasmussen LJH, Gamst-Jensen H, Nehlin JO, Andersen O, Tingleff J. Stauning MA, et al. Among authors: kallemose t. J Emerg Med. 2021 Sep;61(3):298-313. doi: 10.1016/j.jemermed.2021.03.012. Epub 2021 Mar 26. J Emerg Med. 2021. PMID: 34092446 Free PMC article.
Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: a cluster-randomized clinical trial (TRIAGE III).
Schultz M, Rasmussen LJH, Andersen MH, Stefansson JS, Falkentoft AC, Alstrup M, Sandø A, Holle SLK, Meyer J, Törnkvist PBS, Høi-Hansen T, Kjøller E, Jensen BN, Lind M, Ravn L, Kallemose T, Lange T, Køber L, Rasmussen LS, Eugen-Olsen J, Iversen KK. Schultz M, et al. Among authors: kallemose t. Scand J Trauma Resusc Emerg Med. 2018 Aug 28;26(1):69. doi: 10.1186/s13049-018-0539-5. Scand J Trauma Resusc Emerg Med. 2018. PMID: 30153859 Free PMC article. Clinical Trial.
Availability of suPAR in emergency departments may improve risk stratification: a secondary analysis of the TRIAGE III trial.
Schultz M, Rasmussen LJH, Kallemose T, Kjøller E, Lind MN, Ravn L, Lange T, Køber L, Rasmussen LS, Eugen-Olsen J, Iversen K. Schultz M, et al. Among authors: kallemose t. Scand J Trauma Resusc Emerg Med. 2019 Apr 11;27(1):43. doi: 10.1186/s13049-019-0621-7. Scand J Trauma Resusc Emerg Med. 2019. PMID: 30975178 Free PMC article. Clinical Trial.
Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.
Azam TU, Shadid HR, Blakely P, O'Hayer P, Berlin H, Pan M, Zhao P, Zhao L, Pennathur S, Pop-Busui R, Altintas I, Tingleff J, Stauning MA, Andersen O, Adami ME, Solomonidi N, Tsilika M, Tober-Lau P, Arnaoutoglou E, Keitel V, Tacke F, Chalkias A, Loosen SH, Giamarellos-Bourboulis EJ, Eugen-Olsen J, Reiser J, Hayek SS; International Study of Inflammation in COVID-19. Azam TU, et al. J Am Soc Nephrol. 2020 Nov;31(11):2725-2735. doi: 10.1681/ASN.2020060829. Epub 2020 Sep 22. J Am Soc Nephrol. 2020. PMID: 32963090 Free PMC article.
121 results